6533b857fe1ef96bd12b3bbc
RESEARCH PRODUCT
Guidelines from the 2017 European Conference on Infections in Leukaemia for management of HHV-6 infection in patients with hematologic malignancies and after hematopoietic stem cell transplantation
Christine RobinKatherine N. WardRoberto CrocchioloJoshua A. HillRafael De La CámaraPer LjungmanHermann EinseleCatherine CordonnierDavid NavarroPetr Hubaceksubject
Oncologymedicine.medical_specialtyHHV-6 Infectionmedicine.medical_treatmentvirusesHerpesvirus 6 HumanGraft vs Host DiseaseRoseolovirus InfectionsDiseaseHematopoietic stem cell transplantationAntiviral AgentsGuideline ArticleImmunocompromised HostInternal medicinemedicineCombined Modality TherapyHumansIn patientbiologybusiness.industryHematopoietic Stem Cell Transplantationvirus diseasesHematologybiochemical phenomena metabolism and nutritionbiology.organism_classificationmedicine.diseaseCell Transformation ViralCombined Modality TherapyEuropeTreatment OutcomeHematologic NeoplasmsPractice Guidelines as TopicHuman herpesvirus 6Allogeneic hematopoietic stem cell transplantbusinessEncephalitisdescription
Of the two human herpesvirus 6 (HHV-6) species, human herpesvirus 6B (HHV-6B) encephalitis is an important cause of morbidity and mortality after allogeneic hematopoietic stem cell transplant. Guidelines for the management of HHV-6 infections in patients with hematologic malignancies or post-transplant were prepared a decade ago but there have been no other guidelines since then despite significant advances in the understanding of HHV-6 encephalitis, its therapy, and other aspects of HHV-6 disease in this patient population. Revised guidelines prepared at the 2017 European Conference on Infections in Leukaemia covering diagnosis, preventative strategies and management of HHV-6 disease are now presented.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2019-08-29 | Haematologica |